Mechl Z, Kopecný J
Arch Geschwulstforsch. 1986;56(5):367-71.
The paper presents the results of three randomized trials for adjuvant chemo- and immunotherapy in malignant melanoma clinical stage II: 770 patients were treated by surgery, surgery + DTIC, surgery + BCG or surgery + DTIC + BCG, 248 patients were treated by surgery or surgery + poly-U-A; 40 patients were treated by surgery or surgery + vinblastine/bleomycine/cisplatinum. Neither the recidive free interval nor the survival could be enhanced by surgically adjuvant chemo- and immunotherapy in this group of patients.
本文介绍了三项关于恶性黑色素瘤临床II期辅助化疗和免疫治疗的随机试验结果：770例患者接受了手术、手术+达卡巴嗪、手术+卡介苗或手术+达卡巴嗪+卡介苗治疗，248例患者接受了手术或手术+聚尿苷酸治疗；40例患者接受了手术或手术+长春碱/博来霉素/顺铂治疗。在这组患者中，手术辅助化疗和免疫治疗并不能延长无复发间期或提高生存率。
